Hans Ivar Robinson
Amministratore Delegato presso Birk Venture AS
Profilo
Hans Ivar Robinson is the founder of Birk Venture AS, founded in 2010, where he holds the title of Managing Director & Chairman.
He is also the founder of Zelluna Immunotherapy AS, founded in 2016, where he holds the title of Chairman.
Mr. Robinson's current job(s) include being the Chairman of Nextera.
AS since 2010 and a Director at Accession Therapeutics Limited.
Mr. Robinson's former job(s) include being a Non-Executive Director at BerGenBio ASA, a Director at APIM Therapeutics AS, a Director at Circio Holding ASA, and a Principal at AstraZeneca AS.
He was also the Vice President-Investor Relations at Pronova BioPharma ASA from 2007 to 2009 and a Principal at Pfizer AS.
Mr. Robinson obtained a graduate degree from the Norwegian School of Economics & Business Administration.
Posizioni attive di Hans Ivar Robinson
Società | Posizione | Inizio |
---|---|---|
Birk Venture AS
Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects. | Amministratore Delegato | 05/02/2010 |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Presidente | 01/01/2010 |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Fondatore | 01/01/2016 |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Hans Ivar Robinson
Società | Posizione | Fine |
---|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | Public Communications Contact | 01/12/2009 |
CIRCIO HOLDING ASA | Direttore/Membro del Consiglio | - |
Pfizer AS
Pfizer AS Pharmaceuticals: MajorHealth Technology Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway. | Corporate Officer/Principal | - |
AstraZeneca AS | Corporate Officer/Principal | - |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Direttore/Membro del Consiglio | - |
Formazione di Hans Ivar Robinson
Norwegian School of Economics & Business Administration | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BERGENBIO ASA | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Aziende private | 8 |
---|---|
AstraZeneca AS | |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | Health Technology |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Commercial Services |
Pfizer AS
Pfizer AS Pharmaceuticals: MajorHealth Technology Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway. | Health Technology |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Health Technology |
Birk Venture AS
Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects. | Finance |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Health Technology |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Health Technology |
- Borsa valori
- Insiders
- Hans Ivar Robinson